Evidence map›Paper›PMID 36924249›Full record

ArticleHaematologica2023

The Glanzmann Thrombasthenia Registry: safety of platelet therapy in patients with Glanzmann thrombasthenia and changes in alloimmunization status.

Man-Chiu Poon, Roseline D'Oiron, Sibin Baby, Rainer B Zotz, Giovanni Di Minno

Abstract readLetter
PubMed Full text at PMC Publisher
In one paragraph

Article in Haematologica, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 4 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
4citing papers in PubMed, 1 pooled it
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

4 citing papers in PubMed, 1 synthesis or guideline pooled it.

  1. Efficacy and safety of recombinant activated factor VII in Glanzmann thrombasthenia: A systematic literature review.Haemophilia : the official journal of the World Federation of Hemophilia · 2025
    Pooled it
  2. Article
  3. Obstetric and Gynaecological Challenges and Outcomes in Women and Girls With Glanzmann's Thrombasthenia.Haemophilia : the official journal of the World Federation of Hemophilia · 2025
    Article
  4. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

5 authors.

Man-Chiu PoonDepartments of Medicine, Pediatrics and Oncology, Cumming School of Medicine, University of Calgary, Calgary, Alberta, Canada; Southern Alberta Rare Blood and Bleeding Disorders Comprehensive Care Program, Foothills Medical Centre, Calgary, Alberta. mcpoon@ucalgary.ca.
Roseline D'OironCentre de Référence de l'Hémophilie et des Maladies Hémorragiques Constitutionnelles, Hôpital Bicêtre, AP-HP, and HITh, UMR_S1176, INSERM. Université Paris Saclay, Le Kremlin-Bicêtre.
Sibin BabyBiostatistics and Programming GD GBS, Novo Nordisk Service Centre India Private Ltd, Whitefield, Bangalore.
Rainer B ZotzInstitute for Laboratory Medicine, Blood Coagulation and Transfusion Medicine (LBT), Düsseldorf, Germany; Department of Hemostasis, Hemotherapy and Transfusion Medicine, Heinrich Heine University Medical Centre, Düsseldorf.
Giovanni Di MinnoDepartment of Clinical Medicine and Surgery, Regional Reference Center for Coagulation Disorders, Federico II University, Naples.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

PubMed holds no abstract for this paper.

Indexed as

ThrombastheniaBlood PlateletsFactor VIIaHumansRegistriesFactor VIIa

Identifiers

PMID36924249
PMCPMC10542831

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.